Jump to content

Abionic

Edit links
From Wikipedia, the free encyclopedia
Abionic SA
Company typePrivate
IndustryDiagnostic in vitro, ultra-rapid
Founded2010 in Lausanne, Switzerland
FoundersNicolas Durand, Iwan Märki
Headquarters
Epalinges
,
Switzerland
ProductsabioSCOPE, IVD CAPSULE
Number of employees
60
SubsidiariesAbionic USA, Inc. (U.S,), Abionic HK Ltd 愛必尼克有限公司 (Hong Kong)
Websitewww.abionic.com

Abionic SA is a company specialized in the development of ultra-rapid in vitro diagnostic tests, located in Lausanne, Switzerland.[1]

Abionic has developed the abioSCOPE, a point-of-care diagnostic platform using its patented nanofluidic technology. The abioSCOPE is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP). Secreted mainly by the pancreas and stomach, PSP rises rapidly in the blood in case of sepsis development and up to 72 hours before today's standard of care.[2] Thus, this is a good and sensitive warning signal to guide doctors in their decision to start antibiotic treatment. Besides the diagnostic value of PSP for sepsis, its availability at the bedside and the availability of the result in 5 minutes provides an additional opportunity to closely monitor patients at risk of developing sepsis.

The abioSCOPE is also used in primary care for the screening of iron deficiency, respiratory allergies[3] and more recently for COVID-19 screening with an antigenic saliva and nasopharyngeal test.

History

[edit]

Abionic was founded in 2010 at the Swiss Federal Institute of Technology in Lausanne (EPFL, École Polytechnique Fédérale de Lausanne) by Dr Nicolas Durand and Dr Iwan Märki.[4]

Highlights of the company's development:

2012:

  • First demonstration of the technology
  • The company obtains ISO 13485:2003
  • Fundraising of 3.5 million Swiss francs in series A[4]
  • Abionic receives the Swiss Excellence Product Award

2014: Fund-raising of 8.2 million Swiss francs in series B

2015: First prototype allergy panel ready[5]

2016:

  • New facilities inauguration in Biopôle, Lausanne
  • ISO certified automated production line
  • Abionic becomes the ambassador of the Swiss Health Valley
  • Signature of a first distribution contract on the Swiss market[6]

2017 :

  • CE mark for the IVD CAPSULE PSP test for early sepsis diagnosis[7]
  • CE mark for the IVD CAPSULE Ferritin test[7]
  • First allergy panel test registered at the FDA[8]
  • Partnership with the Global Sepsis Alliance (GSA), and sponsor of World Sepsis Day[9]
  • Fundraising of 25 million Swiss francs in series C

2018:

  • ISO 13485:2016 certification obtained
  • Sepsis impact study in 14 ICUs in 4 EU countries, for the use of the IVD CAPSULE PSP test on the abioSCOPE in the ICUs

2019:

  • Sepsis impact study in the United States, for the use of the IVD CAPSULE PSP test on the abioSCOPE in the ICUs
  • CE mark for the abioSCOPE 2.0

2020: Start of the commercialisation of the abioSCOPE 2.0

2021:

  • Distribution of IVD CAPSULE PSP in over 40 countries
  • CE mark for the IVD CAPSULE COVID-19 Antigenic Saliva Swab test[10]

'2022:

  • CE mark for the IVD CAPSULE COVID-19 Antigenic Nasopharyngeal test
  • Increase of the company's production capacity to 2 million kits per year

Increase of the tests' portfolio with the development of D-Dimer (thrombosis) and CRP (inflammation) tests.

Products

[edit]

Abionic's solution is composed of the abioSCOPE, an in vitro diagnostic device and the consumable called the IVD CAPSULE, which is a single-use and analyte-specific tests. Test principle :

The test is based on mixing the patient's sample (whole blood, capillary, serum, saliva or nasopharyngeal sample) with a reagent containing fluorescent markers. The solution is then deposited on the capsule and enters nanochannels by capillary action. The volume-to-surface ratio then forces the molecules to interact immediately together, limiting their travel distance and reducing the incubation time to a few minutes. The concentration of the molecule of interest is then proportional to the intensity of the fluorescent signal measured by the abioSCOPE.

The different diagnostic tests developed by Abionic
  • The IVD CAPSULE PSP is a quantitative serological test providing results within five minutes for the early detection of sepsis. PSP concentration increases rapidly and up to 72 hours before the onset of clinical symptoms. Its availability at the patient's bedside provides an additional tool to assist healthcare professionals in the management of antibiotic treatment and helps to limit the development of bacterial resistance, which is a major public health issue.
The abioSCOPE and the IVD CAPSULE PSP
  • The IVD CAPSULE Ferritin is a quantitative serological test providing results within 5 minutes from a 50 μL sample of capillary blood. It is intended to be used by healthcare professionals to identify iron deficiencies, affecting mainly pregnant women, people with chronic diseases (heart failure, kidney disease, etc.), bleeding (ulcers) and inability to absorb iron.
The abioSCOPE and the IVD CAPSULE Ferritin
  • The IVD CAPSULE COVID-19 is a qualitative test performed with a saliva or nasopharyngeal sample and which provides a result within 2 minutes. It identifies the presence of the SARS-CoV-2 to identify contagious individuals and reduce virus spread.
The abioSCOPE and the IVD CAPSULE COVID-19
  • The IVD CAPSULE Aeroallergens is a semi-quantitative serological test at the point-of-care. It provides results within 12 minutes from a 50 μl sample of capillary blood. It is composed of 7 key allergens (IgE) to help diagnose allergic asthma: Dog (Can f 1), cat (Fed d 1), dust mites (Der p 1 + Der p 2), Alternaria Alternata (Alt a 1) and timothy grass (Phl p 1 + Phl p 5).

Other tests are under development: D-Dimer, CRP, PCT.

Recognition and awards

[edit]
Year Name of competition Rank Location
2010 PERL (Prix Entreprendre Région Lausanne) 1st[11] Lausanne
DebioPharm Award for Life sciences 1st[12] Switzerland
KPMG Inspiration winner[13] Switzerland
Venture Kick winner of all 3 stages Switzerland
2011 DeVigier winner[14] Switzerland
2012 European Academic Enterprise Awards 2012[15] 2nd Europe
Venture (Phase 2 Business Plan)[16] 6th Switzerland
Red Herring top 100 best European Startups[17] winner Europe
2013 Swiss Excellence Product Award winner[18] Switzerland
Best Elevator Pitch Award[19] winner Luxembourg
2016 Swiss Economic Forum finalist[20] Switzerland
2017 Finance Monthly Game Changers Awards winner[21] Switzerland
2018 EY Entrepreneur of the Year 2018 finalist[22] Switzerland
Swiss Venture Club Award 2018 Finalist[23] Switzerland

References

[edit]
  1. ^ "World's Fastest Sepsis Test from Abionic Produces Result in Five Minutes when tested in Patients at London and Zurich Hospitals | Abionic". abionic.com. Retrieved July 29, 2024.
  2. ^ Eggimann, Philippe; Que, Yok-Ai; Rebeaud, Fabien (February 28, 2019). "Measurement of Pancreatic Stone Protein in the Identification and Management of Sepsis". Biomarkers in Medicine. 13 (2): 135–145. doi:10.2217/bmm-2018-0194. PMID 30672312. Retrieved July 29, 2024 – via CrossRef.
  3. ^ "Abionic prépare le terrain médical avec ses tests d'allergie ultrarapides - Le Temps". Le Temps (in French). October 24, 2017. Retrieved July 29, 2024.
  4. ^ a b "About Us | Abionic". abionic.com. Retrieved July 29, 2024.
  5. ^ "Abionic starts the commercialization of its revolutionary diagnostic platfrom". www.venturelab.swiss. Retrieved July 29, 2024.
  6. ^ ""Abionic extends its range of tests"" (PDF). Retrieved July 29, 2024.
  7. ^ a b Wilson, Elaine Sanchez (February 7, 2017). "POC Tests for Sepsis, Iron Deficiency, Get CE Mark". Retrieved July 29, 2024.
  8. ^ "Abionic has received US Food and Drug Administration (FDA) registration for detecting allergie"
  9. ^ "The GSA Welcomes Abionic as the Newest Sponsor of World Sepsis Day". Global Sepsis Alliance. July 10, 2017. Retrieved July 29, 2024.
  10. ^ "Abionic launches ultra-fast on site COVID-19 Saliva Test aimed at schools, hotels, airports and restaurants". www.prnewswire.co.uk. Retrieved July 29, 2024.
  11. ^ "PERL édition 2010 | Lausanne Région". www.lausanneregion.ch. August 31, 2016. Retrieved July 29, 2024.
  12. ^ Debiopharm Group Press Release (November 2010) "Abionic wins the 'Prix Debiopharm Valais pour les Sciences de la Vie", www.debiopharm.com
  13. ^ "Abionic décroche deux nouvelles reconnaissances : les SEF High Potential & Finance Monthly Game Changers Awards | Abionic". abionic.com. Retrieved July 29, 2024.
  14. ^ W.A. De Vigier Stiftung (2011) "Abionic, winner of the De Vigier 2011 Award"
  15. ^ Venture Kick (December 2012) "Abionic und Optotune im Finale der ACES Awards 2012", www.venturekick.ch
  16. ^ "Teams 2012 – Winners Phase 2". www.venture.ch. Archived from the original on 2018-08-14.
  17. ^ Red Herring (2012) "Europe 2012 Top 100", www.redherring.com
  18. ^ Venturelab (2013) "Des venturelab alumni récompensés au "Swiss Excellence Product Award"", www.venturelab.ch
  19. ^ Venture Kick (April 2013) ""Abionic gewinnt den „Best Elevator Pitch Award"", www.venturekick.ch
  20. ^ Swiss Economic Forum (2016) "Swiss Economic Forum".
  21. ^ Finance Monthly (2017) "Game Changers Awards 2017" p.6, www.finance-monthly.com
  22. ^ "Eighteen finalists nominated for the «Entrepreneur of the year» award". startupticker.ch News Startupticker.ch. 2018-10-26. Retrieved 2024-08-05.
  23. ^ EY (September 2018) "Prix SVC 2018", www.swiss-venture-club.ch
[edit]

Media related to Abionic at Wikimedia Commons

Retrieved from "https://en.wikipedia.org/w/index.php?title=Abionic&oldid=1238836156"